JCR Pharmaceuticals has entered into an exclusive license agreement with Italfarmaco for the development and commercialization of JR-141 in the U.S., Europe and other regions. The agreement provides for upfront payments, milestones and royalties, and clarifies roles for global rollout and manufacturing supply. This expands long-term collaborations in rare disease areas.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4552","jir_company_name":"JCR Pharmaceuticals Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4552-20261002-01.pdf","jir_short_summary":"JCR Pharmaceuticals has entered into an exclusive license agreement with Italfarmaco for the development and commercialization of JR-141 in the U.S., Europe and other regions. The agreement provides for upfront payments, milestones and royalties, and clarifies roles for global rollout and manufacturing supply. This expands long-term collaborations in rare disease areas.","jir_summary":"### Overview of the Strategic Partnership\nJCR Pharmaceuticals Co., Ltd. has entered into an exclusive license agreement granting Italfarmaco rights to develop and commercialize JR-141, which has marketing approval in Japan, in the United States, Europe and Latin America. Following regulatory approvals, Italfarmaco will be responsible for sales and distribution, while JCR Pharmaceuticals Co., Ltd. will continue manufacturing. The agreement creates entitlement to an upfront payment, milestone payments, royalties and consideration for supply.\n\n### Outlook and Strategic Significance\nThis agreement expands strategic partnerships in rare disease areas and strengthens the cooperative framework, following the exclusive license agreement for givinostat in Japan signed in December 2025. By combining Italfarmaco's global development and distribution capabilities with the J-Brain Cargo technology, the partners aim to broaden new treatment options for patients with Hunter syndrome.","jir_financial_highlights":"Upfront payment: Unknown (Unknown)\nMilestones and royalties: Unknown (Unknown)\nConsideration for product supply: Unknown (Unknown)","jir_category":"","jir_hashtags":"#NotAShareBuyback, #RareDiseasePartnership","jir_key_figures":"Upfront payment: Unknown\nMilestones and royalties: Unknown\nProduct supply consideration: Unknown","jir_meta_title":"JCR Pharmaceuticals Co., Ltd. Exclusive License Agreement with Italfarmaco for JR-141 Development and Commercialization in the U.S. and Europe\uff5cOctober 2026","jir_meta_description":"JCR Pharmaceuticals Co., Ltd. has signed an exclusive license agreement with Italfarmaco for development and commercialization of JR-141, a Hunter syndrome treatment, in the U.S., Europe and other regions. The agreement foresees upfront payments and royalties, with manufacturing to continue by JCR Pharmaceuticals Co., Ltd. This advances partnership expansion in rare disease areas.","jir_og_title":"JCR Pharmaceuticals Co., Ltd. Exclusive License with Italfarmaco for JR-141 in the U.S. and Europe\uff5cOctober 2026","jir_og_description":"JCR Pharmaceuticals Co., Ltd. has entered an exclusive license agreement with Italfarmaco for JR-141\u2019s expansion into the U.S. and Europe. Upfront payments are expected; manufacturing will continue with JCR Pharmaceuticals Co., Ltd., and sales\/distribution will be handled by Italfarmaco. This supports long-term expansion of collaborations in rare diseases.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9680,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-127039","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n